Shares of Adamas Pharmaceuticals Inc. (ADMS) have lost more than 9% of their value year to date while the iShares Nasdaq Biotechnology Index (ETF) (IBB) is up more than 14% during the same period.
Adamas is focused on developing new medicines for chronic neurologic conditions like Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s disease.
The Company’s lead program is ADS-5102, a high-dose *Amantadine, taken once-daily at bedtime, in development for levodopa-induced dyskinesia (LID) in people with Parkinson’s disease.
*Amantadine is an antiviral medication used to prevent or treat certain influenza infections and is also prescribed to relieve symptoms of Parkinson’s disease. The drug is also effective in relieving fatigue in multiple sclerosis.
Parkinson’s disease is a degenerative disorder of the central nervous system characterized by tremor, or shaking often in a hand or leg, and stiff muscles. It is estimated that over 1.5 million people in the U.S. have Parkinson’s disease. Levodopa remains the gold standard to treat Parkinson’s symptoms.
A common and severe complication of the Levodopa therapy is dyskinesia, which refers to non-purposeful, fragmented or jerky motions. Approximately 200,000 Parkinson’s disease patients suffer from Levodopa-induced dyskinesia, or LID.
Adamas’ drug candidate for levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, ADS-5102, is under FDA review – with a decision expected to be announced on August 24, 2017.
In phase III trials, ADS-5102 demonstrated a primary reduction of LID and a secondary reduction in *OFF time in Parkinson’s disease patients, with a manageable safety and tolerability profile. (*OFF time refers to periods of the day when the medication is not working well, causing worsening of the symptoms. (Source: AgingCare.com).)
If approved, ADS-5102 will be the first and only approved medicine for the indication of levodopa-induced dyskinesia in people with Parkinson’s disease.